Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors



Status:Recruiting
Conditions:Cancer, Brain Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:1 - 21
Updated:4/4/2019
Start Date:March 27, 2014

Use our guide to learn which trials are right for you!

A Phase 1/2 Study of AZD1775 (MK-1775) in Combination With Oral Irinotecan in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors

This phase I/II trial studies the side effects and best dose of adavosertib and irinotecan
hydrochloride in treating younger patients with solid tumors that have come back or that have
not responded to standard therapy. Adavosertib and irinotecan hydrochloride may stop the
growth of tumor cells by blocking some of the enzymes needed for cell growth.

PRIMARY OBJECTIVES:

I. To estimate the maximum tolerated dose (MTD) and/or recommended Phase 2 dose of
adavosertib (AZD1755 [MK-1775]) administered on days 1 through 5 every 21 days, in
combination with oral irinotecan (irinotecan hydrochloride), to children with recurrent or
refractory solid tumors.

II. To define and describe the toxicities of AZD1755 (MK-1775) in combination with oral
irinotecan administered on this schedule.

III. To characterize the pharmacokinetics of AZD1755 (MK-1775) in children with refractory
cancer.

SECONDARY OBJECTIVES:

I. To preliminarily define the antitumor activity of AZD1755 (MK-1775) and irinotecan within
the confines of a Phase 1 study.

II. To obtain initial Phase 2 efficacy data on the anti-tumor activity of AZD1755 (MK-1775)
in combination with irinotecan administered to children with relapsed or refractory
neuroblastoma, in children with relapsed or refractory medulloblastoma/CNS PNET (central
nervous system primitive neuroectodermal tumor) and in children with relapsed or refractory
rhabdomyosarcoma.

III. To investigate checkpoint over-ride by AZD1755 (MK-1775) via the mechanism-based
pharmacodynamic (PD) biomarker of decreased cyclin-dependent kinase 1 (CDK1) phosphorylation
in correlative and exploratory studies.

IV. To evaluate potential predictive biomarkers of AZD1755 (MK-1775) sensitivity, including
v-myc avian myelocytomatosis viral oncogene homolog (MYC), v-myc avian myelocytomatosis viral
oncogene neuroblastoma derived homolog (MYCN), phosphorylated-WEE1 G2 checkpoint kinase
(p-Wee1), enhancer of zeste homolog 2 (Drosophila) (EZH2) and gamma-H2A histone family,
member gamma-H2AX in tumor tissues in correlative and exploratory studies.

OUTLINE: This is a phase I, dose-escalation followed by a phase II study.

Patients receive irinotecan hydrochloride orally (PO) and adavosertib PO on days 1-5.
Treatment repeats every 21 days for 18 cycles in the absence of disease progression or
unacceptable toxicity.

After completion of study treatment, patients are followed up periodically.

Inclusion Criteria:

- Patients must have had histologic verification of malignancy at original diagnosis or
relapse except in patients with intrinsic brain stem tumors, optic pathway gliomas, or
patients with pineal tumors and elevations of cerebrospinal fluid (CSF) or serum tumor
markers including alpha-fetoprotein or beta-human chorionic gonadotropin (HCG)

- Part A: Patients with relapsed or refractory solid tumors, including patients with
primary or metastatic CNS tumors

- Part B: Patients with relapsed or refractory neuroblastoma

- Part C: Patients with relapsed or refractory medulloblastoma or CNS embryonal tumors
formally classified as PNET (pineoblastoma, CNS neuroblastoma, CNS
ganglioneuroblastoma, embryonal tumor with multi-layered rosettes, medulloepithelioma,
CNS embryonal tumor with rhabdoid features (INI1 intact) and CNS embryonal tumor, not
otherwise specified)

- Part D: Patients with relapsed or refractory rhabdomyosarcoma

- Patients must have a body surface area >= 0.35 m^2 at the time of study enrollment if
enrolling on dose levels 1-5; patients must have a body surface area >= 0.46 m^2 at
the time of study enrollment if enrolling on dose level 0

- Part A: Patients must have either measurable or evaluable disease

- Part B: Patients must have either measurable disease or must be evaluable for MIBG
response without evidence of Response Evaluation Criteria in Solid Tumors (RECIST)
measurable lesions; patients with neuroblastoma in bone marrow only are not eligible

- Part C: Patients must have measurable disease by computed tomography (CT) or magnetic
resonance imaging (MRI)

- Part D: Patients must have measurable disease for Part D

- Patient's current disease state must be one for which there is no known curative
therapy or therapy proven to prolong survival with an acceptable quality of life

- Karnofsky >= 50% for patients > 16 years of age and Lansky >= 50 for patients =< 16
years of age; note: neurologic deficits in patients with CNS tumors must have been
relatively stable for at least 7 days prior to study enrollment; patients who are
unable to walk because of paralysis, but who are up in a wheelchair, will be
considered ambulatory for the purpose of assessing the performance score

- Patients must have fully recovered from the acute toxic effects of all prior
anti-cancer chemotherapy

- At least 21 days after the last dose of myelosuppressive chemotherapy (42 days if
prior nitrosourea)

- At least 14 days after the last dose of a long-acting growth factor (e.g. Neulasta) or
7 days for short-acting growth factor; for agents that have known adverse events
occurring beyond 7 days after administration, this period must be extended beyond the
time during which adverse events are known to occur; the duration of this interval
must be discussed with the study chair

- At least 7 days after the last dose of a biologic agent; for agents that have known
adverse events occurring beyond 7 days after administration, this period must be
extended beyond the time during which adverse events are known to occur; the duration
of this interval must be discussed with the study chair

- At least 42 days after the completion of any type of immunotherapy, e.g. tumor
vaccines

- >= 21 days must have elapsed from infusion of lase dose of antibody, and toxicity
related to prior antibody therapy must be recovered to grade =< 1

- At least 14 days after local palliative radiation therapy (XRT) (small port); at least
150 days must have elapsed if prior traumatic brain injury (TBI), craniospinal XRT or
if >= 50% radiation of pelvis; at least 42 days must have elapsed if other substantial
bone marrow radiation, including therapeutic doses of Iobenguane (MIBG)

- Stem cell Infusion without TBI: no evidence of active graft vs host disease and at
least 84 days must have elapsed after transplant or stem cell infusion

- Patients previously treated with irinotecan are eligible for this study

- For patients with solid tumors without known bone marrow involvement: peripheral
absolute neutrophil count (ANC) >= 1000/mm^3

- For patients with solid tumors without known bone marrow involvement: platelet count
>= 100,000/mm^3 (transfusion independent, defined as not receiving platelet
transfusions for at least 7 days prior to enrollment)

- For patients with solid tumors without known bone marrow involvement: hemoglobin >=
8.0 g/dL (may receive red blood cell [RBC] transfusions)

- Patients with known bone marrow metastatic disease will be eligible for study provided
they meet the blood counts (may receive transfusions provided they are not known to be
refractory to red cell or platelet transfusions); these patients will not be evaluable
for hematologic toxicity; at least 2 of every cohort of 3 patients must be evaluable
for hematologic toxicity for Part A, the dose escalation part of the study; if
dose-limiting hematologic toxicity is observed, all subsequent patients enrolled must
be evaluable for hematologic toxicity

- Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70
ml/min/1.73 m^2 or a serum creatinine based on age/gender as follows:

- Age 1 to < 2 years: 0.6 mg/dL

- Age 2 to < 6 years: 0.8 mg/dL

- Age 6 to < 10 years: 1 mg/dL

- Age 10 to < 13 years: 1.2 mg/dL

- Age 13 to < 16 years: 1.5 mg/dL (males), 1.4 mg/dL (females)

- Age >= 16 years: 1.7 mg/dL (males), 1.4 mg/dL (females)

- Bilirubin (sum of conjugated + unconjugated) =< 1.5 x upper limit of normal (ULN) for
age

- Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 135
U/L; for the purpose of this study, the ULN for SGPT is 45 U/L

- Serum albumin >= 2 g/dL

- Correct QT interval (QTc) =< 480 msec; Note: Patients should avoid concomitant
medication known or suspected to prolong QTc interval or cause torsades de pointes; if
possible, alternative agents should be considered; patients who are receiving drugs
that prolong the QTc are eligible if the drug is necessary and no alternatives are
available

- Patients with seizure disorder may be enrolled if on non-enzyme inducing
anticonvulsants and well controlled

- Nervous system disorders (Common Terminology Criteria for Adverse Events version 5.0
[CTCAE v5.0]) resulting from prior therapy must be =< grade 2, with the exception of
decreased tendon reflex (DTR); any grade of DTR is eligible

- All patients and/or their parents or legally authorized representatives must sign a
written informed consent; assent, when appropriate, will be obtained according to
institutional guidelines

- Tissue blocks or slides must be sent if available, with exclusions; if tissue blocks
or slides are unavailable, the study chair must be notified prior to study enrollment

- Patients must be able to swallow capsules

Exclusion Criteria:

- Pregnant or breast-feeding women may not be entered on this study; pregnancy tests
must be obtained in girls who are post-menarchal

- Males or females of reproductive potential may not participate unless they have agreed
to use an effective double barrier contraceptive method for the entire duration of
protocol therapy and for 3 months (males) and 1 month (females) after study drug
discontinuation

- Patients receiving corticosteroids who have not been on a stable or decreasing dose of
corticosteroid for at least 7 days prior to enrollment are not eligible

- Patients who are currently receiving another investigational drug are not eligible

- Patients who are currently receiving other anti-cancer agents are not eligible

- Patients who are currently receiving drugs that are strong or moderate inhibitors
and/or inducers of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) or
sensitive CYP3A4 substrates and CYP3A4 substrates with a narrow therapeutic range are
not eligible; the use of aprepitant as an antiemetic is prohibited; caution should be
exercised with concomitant administration of AZD1755 (MK-1775) and agents that are
sensitive substrates of cytochrome P450, family 2, subfamily C, polypeptide 8
(CYP2C8), 2C9 and 2C19, or substrates of this enzyme with narrow therapeutic ranges,
as well as agents that are inhibitors or substrates of permeability glycoprotein
(P-gp)

- Patients who are receiving cyclosporine, tacrolimus or other agents to prevent
graft-versus-host disease post bone marrow transplant are not eligible for this trial

- Patients must not have received enzyme inducing anticonvulsants for at least 14 days
prior to enrollment

- Patients with cardiac diseases ongoing or in the past 6 months (e.g. congestive heart
failure, acute myocardial infarction, significant uncontrolled arrhythmias) are not
eligible for this trial

- Patients who have an uncontrolled infection are not eligible

- Patients who have received a prior solid organ transplantation are not eligible

- Patients who in the opinion of the investigator may not be able to comply with the
safety monitoring requirements of the study are not eligible

- Patients with a history of allergic reaction to irinotecan, cephalosporins or a severe
penicillin allergy are not eligible

- Patients unable to swallow capsules whole are not eligible; nasogastric or gastric (G)
tube administration is not allowed
We found this trial at
24
sites
705 Riley Hospital Dr
Indianapolis, Indiana 46202
(317) 944-5000
Principal Investigator: James M. Croop
Phone: 800-248-1199
Riley Hospital for Children Riley Hospital for Children at IU Health is a place of...
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
1600 7th Avenue
Birmingham, Alabama 35233
(205) 638-9100
Principal Investigator: Gregory K. Friedman
Phone: 888-823-5923
Children's Hospital of Alabama Children
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
3333 Burnet Avenue # Mlc3008
Cincinnati, Ohio 45229
 1-513-636-4200 
Principal Investigator: James I. Geller
Phone: 888-823-5923
Cincinnati Children's Hospital Medical Center Patients and families from across the region and around the...
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
4650 Sunset Blvd
Los Angeles, California 90027
 (323) 660-2450
Principal Investigator: Leo Mascarenhas
Phone: 888-823-5923
Childrens Hospital Los Angeles Children's Hospital Los Angeles is a 501(c)(3) nonprofit hospital for pediatric...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
262 Danny Thomas Pl
Memphis, Tennessee 38105
(901) 495-3300
Principal Investigator: Wayne L. Furman
Phone: 888-823-5923
St. Jude Children's Research Hospital St. Jude is unlike any other pediatric treatment and research...
?
mi
from
Memphis, TN
Click here to add this to my saved trials
1201 W La Veta Ave
Orange, California 92868
(714) 997-3000
Principal Investigator: Josephine H. Haduong
Phone: 888-823-5923
Children's Hospital of Orange County For more than 45 years, CHOC Children’s has been steadfastly...
?
mi
from
Orange, CA
Click here to add this to my saved trials
South 34th Street
Philadelphia, Pennsylvania 19104
 215-590-1000
Principal Investigator: Elizabeth Fox
Phone: 888-823-5923
Children's Hospital of Philadelphia Since its start in 1855 as the nation's first hospital devoted...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
4401 Penn Avenue
Pittsburgh, Pennsylvania 15224
412-692-5325
Principal Investigator: Jean M. Tersak
Phone: 888-823-5923
Children's Hospital of Pittsburgh of UPMC UPMC is one of the leading nonprofit health systems...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
3181 Southwest Sam Jackson Park Road
Portland, Oregon 97239
503 494-8311
Principal Investigator: Suman Malempati
Phone: 503-494-1080
Oregon Health and Science University In 1887, the inaugural class of the University of Oregon...
?
mi
from
Portland, OR
Click here to add this to my saved trials
1540 East Hospital Drive
Ann Arbor, Michigan 48109
(877) 475-6688
Principal Investigator: Rajen Mody
Phone: 888-823-5923
C S Mott Children's Hospital Behind the doors of C.S. Mott Children's Hospital there exist...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Atlanta, Georgia 30322
Principal Investigator: William T. Cash
Phone: 888-823-5923
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
13123 E 16th Ave
Aurora, Colorado 80045
(720) 777-1234
Principal Investigator: Margaret E. Macy
Phone: 888-823-5923
Children's Hospital Colorado At Children's Hospital Colorado, we see more, treat more and heal more...
?
mi
from
Aurora, CO
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Principal Investigator: Steven G. DuBois
Phone: 877-442-3324
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
Chicago, Illinois 60614
Principal Investigator: Stewart Goldman
Phone: 888-823-5923
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Jodi Muscal
Phone: 713-798-1354
?
mi
from
Houston, TX
Click here to add this to my saved trials
9000 W Wisconsin Ave #270
Milwaukee, Wisconsin 53226
(414) 266-2000
Principal Investigator: Michael J. Burke
Phone: 414-955-4727
Children's Hospital of Wisconsin Nothing matters more than our children. At Children's Hospital of Wisconsin,...
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Minneapolis, Minnesota 55455
Principal Investigator: Emily G. Greengard
Phone: 888-823-5923
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
New York, New York 10032
Principal Investigator: Alice Lee
Phone: 212-305-6361
?
mi
from
New York, NY
Click here to add this to my saved trials
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Principal Investigator: Robert J. Hayashi
Phone: 800-600-3606
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
San Francisco, California 94143
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
San Francisco, California 94158
Principal Investigator: Kieuhoa T. Vo
Phone: 877-827-3222
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
4800 Sand Point Way NE
Seattle, Washington 98105
(206) 987-2000
Principal Investigator: Julie R. Park
Phone: 888-823-5923
Seattle Children's Hospital Seattle Children’s Hospital specializes in meeting the unique physical, emotional and developmental...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
555 University Avenue
Toronto, Ontario M5G 1X8
Principal Investigator: Sylvain Baruchel
Phone: 416-813-7654
?
mi
from
Toronto,
Click here to add this to my saved trials
111 Michigan Ave NW
Washington, District of Columbia
(202) 476-5000
Principal Investigator: Jeffrey S. Dome
Phone: 888-823-5923
Childrens National Medical Center As the nation’s children’s hospital, the mission of Children’s National Medical...
?
mi
from
Washington,
Click here to add this to my saved trials